FDA accepts for priority review New Drug Application (NDA) for Tyvaso DPI (inhaled treprostinil) for treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease

Tyvaso DPI is next-generation dry powder formulation, which if approved in US, is expected to provide more convenient method of administration compared with traditional nebulised Tyvaso (NT). NDA includes data from BREEZE study. Treprostinil only available as IV infusion in UK.

Source:

Biospace Inc.